Arthritis drug can limit progression of of Type 1 diabetes
Waltham, Massachusetts,( United States), December 7, 2023: A common drug used for rheumatoid arthritis – baricitinib – has shown promising results for patients with type 1 diabetes. A world-first trial, published in The New England Journal of Medicine, showed baricitinib could limit the progression of type 1 diabetes if given during patients’ first 100 days after diagnosis. Type 1 diabetes is a lifelong autoimmune disease in which the immune system mistakenly attacks insulin-producing cells in the pancreas, leaving patients unable to regulate their blood glucose levels. Type 1 diabetes was considered a fatal condition until 100 years ago. With the